Company: PETVW
Filing Date: 2025-02-18
Form Type: 8-K
Source: 0001493152-25-007118
Chunk: 2

Company: PetVivo Holdings, Inc.
Filing Date: 2025-02-18
Form: 8-K
Item: Item 7.01
Chunk 2
---
Item
7.01. Regulation FD Disclosure

On
February 14, 2025, the Company issued a press release announcing the entry into the Agreement with VetStem, a copy of which is attached
hereto as Exhibit 99.1.

The
information in this Item 7.01 of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (“ Exchange Act,

This
Current Report on Form 8-K contains forward-looking statements within the meaning of the “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995, including, but not limited to, the Company’s entry into the exclusive global
licensing agreement with VetStem and potential benefits of such agreement, including potential future payments thereunder, anticipated
preclinical and clinical development activities, potential benefits of PrecisePRP and the Company’s other product candidates and
platform; potential expansion into other indications and combinations, including the timing and development activities related to such
expansion; and potential market opportunities for PrecisePRP and the Company’s other product candidates. All statements other than
statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the
expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions,
levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval
is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual
activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties
related to the Company’s ability to advance its product candidates, the receipt and timing of potential regulatory designations,
approvals and commercialization of product candidates and the Company’s ability to successfully leverage Fast Track designation,
the market size for the Company’s product candidates to be smaller than anticipated, clinical trial sites, supply chain and manufacturing
facilities, the Company’s ability to maintain and recognize the benefits of certain designations received by product candidates,
the timing and results of preclinical and clinical trials, the Company’s ability to fund development activities and achieve development
goals, the Company’s ability to protect intellectual property, and the Company’s commercial collaborations with third parties
and other risks and uncertainties described under the heading “ Risk Factors” in documents the Company files from time to
time with the Securities